Sardar Biglari Sells 6,533 Shares of VanEck Biotech ETF (NASDAQ:BBH) Stock

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 6,533 shares of the company’s stock in a transaction that occurred on Wednesday, July 15th. The shares were sold at an average price of $16.71, for a total value of $109,166.43. Following the completion of the transaction, the insider directly owned 3,552,710 shares in the company, valued at $59,365,784.10. This trade represents a 0.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.70, for a total value of $45,908.30.
• On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.73, for a total value of $20,260.03.

VanEck Biotech ETF Stock Performance

BBH stock opened at $204.23 on Friday. VanEck Biotech ETF has a 1-year low of $154.75 and a 1-year high of $212.54. The business has a fifty day moving average price of $193.07 and a 200-day moving average price of $191.95.

Hedge Funds Weigh In On VanEck Biotech ETF

Hedge funds have recently bought and sold shares of the business. Empowered Funds LLC bought a new position in VanEck Biotech ETF during the fourth quarter valued at approximately $38,000. Flagship Harbor Advisors LLC purchased a new stake in VanEck Biotech ETF during the 4th quarter valued at $47,000. Allworth Financial LP raised its stake in VanEck Biotech ETF by 255.0% during the 4th quarter. Allworth Financial LP now owns 426 shares of the company’s stock valued at $81,000 after buying an additional 306 shares during the last quarter. Fifth Third Bancorp bought a new position in shares of VanEck Biotech ETF during the 1st quarter valued at $127,000. Finally, Huntington National Bank bought a new position in shares of VanEck Biotech ETF during the 4th quarter valued at $132,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.